Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484981 | 0.86 | ACACB (0.50) | GAANPSR1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5556095 | 0.85 | SMN1; SMN2 (0.50) | PTPN1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL6577434 | 0.84 | GAA (0.59) | GAANPSR1PTPN1POLBSMN1; SMN2 | |
| SCHEMBL5551276 | 0.83 | LTA4H (0.48) | SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL6185341 | 0.81 | TAS1R3 (0.51) | SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL9000712 | 0.81 | SMN1; SMN2 (0.57) | POLBSMN1; SMN2KDM4ELMNAMAPK1 | |
| SCHEMBL2624372 | 0.80 | GAA (0.62) | GAANPSR1PTPN1POLBKDM4E | |
| SCHEMBL12742268 | 0.79 | GAA (0.57) | GAANPSR1PTPN1POLBSMN1; SMN2 | |
| SCHEMBL435444 | 0.78 | GAA (0.68) | GAANPSR1PTPN1POLBSMN1; SMN2 | |
| SCHEMBL11815554 | 0.78 | GAA (0.72) | GAANPSR1PTPN1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1301750-C | Conjugates of macrocyclic metal complexes with biomolucules and utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy | SCHERING AG (DE) | 2007-02-28 | — | — | CN | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| CN-1541114-A | Conjugates of macrocyclic metal complexes with biomolucules and utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy | ���ֹɷݹ�˾ | 2004-10-27 | — | — | CN | disclosed |
| CN-1533286-A | Macrocyclic metal complexes and use thereof for production of conjugates with biomolecules | ���ֹɷݹ�˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | GAA 814/4885NPSR1 1305/4885PTPN1 4741/4885 |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | GAA 754/4885NPSR1 1976/4885PTPN1 4824/4885 |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | GAA 754/4885NPSR1 1976/4885PTPN1 4824/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | GAA 814/4885NPSR1 1305/4885PTPN1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.